T-knife Therapeutics bags $110M to sharpen solid tumor cell therapy push into the clinic ntaylor Mon, 08/02/2021 - 06:21.: Investors have flocked to T-knife Therapeutics, which has been taking aim at solid tumors, an area where cell therapies have struggled to perform as well as they have in some blood cancers. Just last year, the biotech raised €66 million ($78 million) and now has reeled in a further $110 million to support a multifront push into clinical trials.